Details of the Drug Combination

General Information of Drug Combination (ID: DCQ5DOY)

• Drug Combination Name: Hydrocortisone + Prednisolone
• Indication: Adrenal Insufficiency; Status: Phase 3 [1]
• Component Drugs:
  Hydrocortisone (DMGEMB7): Small molecular drug
  Prednisolone (DMQ8FR2): Small molecular drug

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Hydrocortisone

Disease Entry	ICD 11	Status	REF
Acne vulgaris	ED80	Approved	[2]
Acute adrenal insufficiency	N.A.	Approved	[2]
Addison disease	5A74.0	Approved	[2]
Allergic rhinitis	CA08.0	Approved	[2]
Angioedema	4A00.15	Approved	[2]
Aspiration pneumonitis	N.A.	Approved	[2]
Autoimmune haemolytic anaemia	3A20	Approved	[2]
Blepharoconjunctivitis	N.A.	Approved	[2]
Bursitis	N.A.	Approved	[2]
Cerebral edema	8D60.1	Approved	[2]
Corneal abrasion	NA06.4	Approved	[2]
Corneal ulcer	9A76	Approved	[2]
Crohn disease	DD70	Approved	[2]
Dermatitis herpetiformis	EB44	Approved	[2]
Diamond-Blackfan anemia	N.A.	Approved	[2]
Disorder of orbital region	N.A.	Approved	[2]
Erythema multiforme	N.A.	Approved	[2]
Exanthem	N.A.	Approved	[2]
Gingival disorder	N.A.	Approved	[2]
Granuloma annulare	N.A.	Approved	[2]
Inflammation	1A00-CA43.1	Approved	[3]
Inflammatory bowel disease	DD72	Approved	[2]
Keratitis	N.A.	Approved	[2]
Malignant otitis externa caused by Pseudomonas aeruginosa	N.A.	Approved	[2]
Multiple sclerosis	8A40	Approved	[2]
Mycosis fungoides	2B01	Approved	[2]
Primary cutaneous T-cell lymphoma	N.A.	Approved	[2]
Proctitis	DB33.Z	Approved	[2]
Psoriasis	EA90	Approved	[2]
Psoriatic arthritis	FA21	Approved	[2]
Rheumatic heart disease	N.A.	Approved	[2]
Rosacea	ED90.0	Approved	[2]
Sarcoidosis	4B20.5	Approved	[2]
Serum sickness	N.A.	Approved	[2]
Severe asthma	CA23	Approved	[2]
Systemic lupus erythematosus	4A40.0	Approved	[2]
Tinea corporis	1F28.Y	Approved	[2]
Tinea cruris	1F28.3	Approved	[2]
Ulcerative colitis	DD71	Approved	[2]
Viral pneumonia	N.A.	Approved	[2]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 3	[4]
Congenital adrenal hyperplasia	5A71.01	Phase 2	[5]
Acquired thrombocytopenia	N.A.	Investigative	[2]
Asthma	CA23	Investigative	[2]
Beta-thalassemia major	N.A.	Investigative	[2]
Classic Hodgkin lymphoma	N.A.	Investigative	[2]
Iridocyclitis	N.A.	Investigative	[2]
Phobic disorder	N.A.	Investigative	[2]
Rheumatoid arthritis	FA20	Investigative	[2]
Synovitis	N.A.	Investigative	[2]
Tinea pedis	1F28.2	Investigative	[2]
Trichinellosis	N.A.	Investigative	[2]
Uveitis	9A96.Z	Investigative	[2]

Hydrocortisone Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Glucocorticoid receptor (NR3C1)	TTYRL6O	GCR_HUMAN	Modulator	[12]

Hydrocortisone Interacts with 1 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[13]

Hydrocortisone Interacts with 5 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[14]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Metabolism	[15]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Metabolism	[16]
Steroid 11-beta-hydroxylase (CYP11B1)	DEPE0RD	C11B1_HUMAN	Metabolism	[17]
Aldosterone synthase (CYP11B2)	DE6TYUK	C11B2_HUMAN	Metabolism	[17]

Hydrocortisone Interacts with 108 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Cytochrome P450 11B1, mitochondrial (CYP11B1)	OTKKL894	C11B1_HUMAN	Increases Chemical Synthesis	[18]
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Increases Expression	[19]
Cytochrome P450 3A5 (CYP3A5)	OTSXFBXB	CP3A5_HUMAN	Increases Expression	[20]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Increases Secretion	[21]
Interleukin-8 (CXCL8)	OTS7T5VH	IL8_HUMAN	Decreases Secretion	[22]
Glutathione S-transferase A1 (GSTA1)	OTA7K5XA	GSTA1_HUMAN	Increases Expression	[23]
Protein-glutamine gamma-glutamyltransferase K (TGM1)	OTB8URRI	TGM1_HUMAN	Increases Expression	[24]
GDH/6PGL endoplasmic bifunctional protein (H6PD)	OTO7TNDD	G6PE_HUMAN	Increases Expression	[25]
11-beta-hydroxysteroid dehydrogenase 1 (HSD11B1)	OTO7FJA9	DHI1_HUMAN	Increases Expression	[25]
Disintegrin and metalloproteinase domain-containing protein 12 (ADAM12)	OTZKOTDB	ADA12_HUMAN	Decreases Expression	[26]
Mitogen-activated protein kinase kinase kinase 7 (MAP3K7)	OTUXEASC	M3K7_HUMAN	Decreases Expression	[26]
Integrin alpha-10 (ITGA10)	OTM0V5AO	ITA10_HUMAN	Increases Expression	[26]
Glucocorticoid receptor (NR3C1)	OTCI2YDI	GCR_HUMAN	Decreases Expression	[26]
Integrin alpha-5 (ITGA5)	OT3RCI67	ITA5_HUMAN	Increases Expression	[26]
Amine oxidase A (MAOA)	OT8NIWMQ	AOFA_HUMAN	Increases Expression	[26]
Insulin-like growth factor-binding protein 5 (IGFBP5)	OTRE5V0C	IBP5_HUMAN	Decreases Expression	[26]
Adhesion G protein-coupled receptor E5 (ADGRE5)	OTTSB84Q	AGRE5_HUMAN	Decreases Expression	[26]
Metallothionein-1X (MT1X)	OT9AKFVS	MT1X_HUMAN	Increases Expression	[26]
Collagen alpha-1(VII) chain (COL7A1)	OT3MIRZJ	CO7A1_HUMAN	Decreases Expression	[26]
Forkhead box protein O1 (FOXO1)	OTPJRB6D	FOXO1_HUMAN	Increases Expression	[26]
Peptidyl-prolyl cis-trans isomerase FKBP5 (FKBP5)	OT404F9K	FKBP5_HUMAN	Increases Expression	[26]
Nuclear receptor subfamily 6 group A member 1 (NR6A1)	OTFZOOQ9	NR6A1_HUMAN	Decreases Expression	[26]
Protein prune homolog 2 (PRUNE2)	OTGW2974	PRUN2_HUMAN	Decreases Expression	[26]
Adhesion G-protein coupled receptor G1 (ADGRG1)	OTQBB8NT	AGRG1_HUMAN	Decreases Expression	[26]
Cytochrome P450 2S1 (CYP2S1)	OTKHX4RF	CP2S1_HUMAN	Decreases Expression	[27]
3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 (HSD3B1)	OTNAZVKB	3BHS1_HUMAN	Affects Binding	[28]
Insulin-like growth factor I (IGF1)	OTIIZR61	IGF1_HUMAN	Decreases Expression	[29]
Insulin-like growth factor 1 receptor (IGF1R)	OTXJIF13	IGF1R_HUMAN	Affects Expression	[29]
CCAAT/enhancer-binding protein beta (CEBPB)	OTM9MQIA	CEBPB_HUMAN	Affects Expression	[29]
Steroidogenic acute regulatory protein, mitochondrial (STAR)	OTFEZ5AI	STAR_HUMAN	Decreases Expression	[29]
CCAAT/enhancer-binding protein alpha (CEBPA)	OTOM9OE4	CEBPA_HUMAN	Increases Expression	[29]
11-beta-hydroxysteroid dehydrogenase type 2 (HSD11B2)	OTHF4H9U	DHI2_HUMAN	Decreases Expression	[29]
Low-density lipoprotein receptor (LDLR)	OTH559LU	LDLR_HUMAN	Decreases Expression	[30]
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR)	OTRT3F3U	HMDH_HUMAN	Decreases Expression	[30]
Apolipoprotein B-100 (APOB)	OTH0UOCZ	APOB_HUMAN	Decreases Expression	[30]
RAC-beta serine/threonine-protein kinase (AKT2)	OTBB632K	AKT2_HUMAN	Decreases Expression	[30]
Scavenger receptor class B member 1 (SCARB1)	OTAE1UA1	SCRB1_HUMAN	Decreases Expression	[30]
Toll-like receptor 4 (TLR4)	OTP7ML3S	TLR4_HUMAN	Decreases Expression	[31]
Basic helix-loop-helix ARNT-like protein 1 (BMAL1)	OTMI12L2	BMAL1_HUMAN	Decreases Expression	[11]
Dihydroxyacetone phosphate acyltransferase (GNPAT)	OTF6LWPO	GNPAT_HUMAN	Increases Expression	[9]
ATP-binding cassette sub-family C member 3 (ABCC3)	OTC3IJV4	MRP3_HUMAN	Increases Expression	[32]
Period circadian protein homolog 1 (PER1)	OTVQF3WX	PER1_HUMAN	Increases Expression	[11]
Trehalase (TREH)	OTJE0NOY	TREA_HUMAN	Decreases Activity	[33]
Toll-like receptor 2 (TLR2)	OTGO5P4R	TLR2_HUMAN	Increases Expression	[31]
Rap guanine nucleotide exchange factor 3 (RAPGEF3)	OTMOW4Z4	RPGF3_HUMAN	Increases Expression	[9]
Renin (REN)	OT52GZR2	RENI_HUMAN	Decreases Expression	[34]
Antithrombin-III (SERPINC1)	OTDFATG0	ANT3_HUMAN	Increases Expression	[35]
Natriuretic peptides A (NPPA)	OTMQNTNX	ANF_HUMAN	Increases Expression	[36]
Somatotropin (GH1)	OT92RTRD	SOMA_HUMAN	Increases Expression	[37]
Pro-neuropeptide Y (NPY)	OT4ICV3P	NPY_HUMAN	Affects Expression	[38]
Insulin (INS)	OTZ85PDU	INS_HUMAN	Increases Expression	[36]
Tumor necrosis factor (TNF)	OT4IE164	TNFA_HUMAN	Decreases Expression	[11]
Interleukin-1 alpha (IL1A)	OTPSGILV	IL1A_HUMAN	Decreases Expression	[11]
Interleukin-1 beta (IL1B)	OT0DWXXB	IL1B_HUMAN	Decreases Expression	[39]
Erythropoietin (EPO)	OTZ90CN4	EPO_HUMAN	Increases Expression	[40]
Annexin A1 (ANXA1)	OT5OFDJC	ANXA1_HUMAN	Increases Expression	[9]
Cholesterol side-chain cleavage enzyme, mitochondrial (CYP11A1)	OT2NV3AN	CP11A_HUMAN	Decreases Expression	[41]
Interleukin-6 (IL6)	OTUOSCCU	IL6_HUMAN	Decreases Expression	[35]
Kallikrein-1 (KLK1)	OTFGP3UR	KLK1_HUMAN	Increases Export	[36]
Prostate-specific antigen (KLK3)	OTFGSBFJ	KLK3_HUMAN	Increases Expression	[42]
Involucrin (IVL)	OT4VPNGY	INVO_HUMAN	Decreases Expression	[43]
Pulmonary surfactant-associated protein B (SFTPB)	OTOHS07E	PSPB_HUMAN	Increases Expression	[44]
Mineralocorticoid receptor (NR3C2)	OT0F2V2Z	MCR_HUMAN	Increases Activity	[45]
Monocyte differentiation antigen CD14 (CD14)	OT83GJ47	CD14_HUMAN	Decreases Expression	[31]
C-C motif chemokine 3 (CCL3)	OTW2H3ND	CCL3_HUMAN	Increases Expression	[46]
Androgen receptor (AR)	OTUBKAZZ	ANDR_HUMAN	Affects Activity	[47]
Pulmonary surfactant-associated protein C (SFTPC)	OTIZJD09	PSPC_HUMAN	Increases Expression	[44]
Proliferating cell nuclear antigen (PCNA)	OTHZ1RIA	PCNA_HUMAN	Decreases Expression	[10]
C-C motif chemokine 4 (CCL4)	OT6B8P25	CCL4_HUMAN	Increases Expression	[46]
C-C motif chemokine 2 (CCL2)	OTAD2HEL	CCL2_HUMAN	Decreases Expression	[46]
Hepatocyte growth factor (HGF)	OTGHUA23	HGF_HUMAN	Decreases Expression	[48]
Filaggrin (FLG)	OTE9QDV6	FILA_HUMAN	Decreases Expression	[43]
Loricrin (LORICRIN)	OTFRPVEO	LORI_HUMAN	Decreases Expression	[43]
NF-kappa-B inhibitor alpha (NFKBIA)	OTFT924M	IKBA_HUMAN	Increases Expression	[9]
Dual specificity protein phosphatase 1 (DUSP1)	OTN6BR75	DUS1_HUMAN	Increases Expression	[11]
Cadherin-5 (CDH5)	OTVX0E1Q	CADH5_HUMAN	Increases Localization	[9]
T-lymphocyte activation antigen CD80 (CD80)	OTJBLUQE	CD80_HUMAN	Decreases Expression	[49]
Catenin beta-1 (CTNNB1)	OTZ932A3	CTNB1_HUMAN	Increases Localization	[9]
Nuclear receptor ROR-alpha (RORA)	OTGQT12P	RORA_HUMAN	Increases Expression	[11]
Sterol regulatory element-binding protein 1 (SREBF1)	OTWBRPAI	SRBP1_HUMAN	Increases Expression	[50]
Amiloride-sensitive sodium channel subunit alpha (SCNN1A)	OTE2KVZV	SCNNA_HUMAN	Increases Expression	[51]
T-lymphocyte activation antigen CD86 (CD86)	OTJCSBPC	CD86_HUMAN	Decreases Expression	[49]
Fatty acid synthase (FASN)	OTFII9KG	FAS_HUMAN	Increases Expression	[50]
Carnitine O-palmitoyltransferase 1, liver isoform (CPT1A)	OTI862QH	CPT1A_HUMAN	Decreases Expression	[50]
Amiloride-sensitive sodium channel subunit beta (SCNN1B)	OT61QQTL	SCNNB_HUMAN	Increases Expression	[51]
Amiloride-sensitive sodium channel subunit gamma (SCNN1G)	OTSJYQVQ	SCNNG_HUMAN	Increases Expression	[51]
ATP-citrate synthase (ACLY)	OTRL9ZRP	ACLY_HUMAN	Increases Expression	[50]
Ras-related protein Rap-1A (RAP1A)	OT5RH6TI	RAP1A_HUMAN	Increases Expression	[9]
Tight junction protein ZO-1 (TJP1)	OTBDCUPK	ZO1_HUMAN	Increases Localization	[9]
Acetyl-CoA carboxylase 1 (ACACA)	OT5CQPZY	ACACA_HUMAN	Increases Expression	[50]
Histone deacetylase 1 (HDAC1)	OTQDNOXZ	HDAC1_HUMAN	Increases Expression	[41]
Splicing factor 1 (SF1)	OTLEDM2S	SF01_HUMAN	Decreases Expression	[41]
Cryptochrome-1 (CRY1)	OTTGAJT0	CRY1_HUMAN	Increases Expression	[11]
Atypical chemokine receptor 1 (ACKR1)	OT9M11LX	ACKR1_HUMAN	Increases Expression	[9]
Occludin (OCLN)	OTSUTVWL	OCLN_HUMAN	Increases Expression	[9]
Patatin-like phospholipase domain-containing protein 2 (PNPLA2)	OTR3ERMR	PLPL2_HUMAN	Decreases Expression	[50]
NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	OTAYZMOY	SIR1_HUMAN	Decreases Expression	[50]
TSC22 domain family protein 3 (TSC22D3)	OT03UM03	T22D3_HUMAN	Increases Expression	[9]
Corticoliberin (CRH)	OT2MOC4T	CRF_HUMAN	Increases Abundance	[52]
Oxytocin-neurophysin 1 (OXT)	OT48M72Z	NEU1_HUMAN	Affects Abundance	[53]
Aldo-keto reductase family 1 member D1 (AKR1D1)	OTBDJ6RL	AK1D1_HUMAN	Increases Reduction	[54]
Angiotensinogen (AGT)	OTBZLYR3	ANGT_HUMAN	Increases Secretion	[55]
Insulin-like growth factor II (IGF2)	OTJ4O6MW	IGF2_HUMAN	Increases Secretion	[56]
Histone-binding protein RBBP7 (RBBP7)	OTLB56HX	RBBP7_HUMAN	Affects Response To Substance	[57]
Glycodelin (PAEP)	OTQA0NV4	PAEP_HUMAN	Increases Metabolism	[58]
Pro-opiomelanocortin (POMC)	OTV41F7T	COLI_HUMAN	Increases Abundance	[59]
T-box transcription factor TBX19 (TBX19)	OTXEMR2U	TBX19_HUMAN	Decreases Abundance	[60]
Interferon beta (IFNB1)	OTYQGUB5	IFNB_HUMAN	Decreases Secretion	[56]

Indication(s) of Prednisolone

Disease Entry	ICD 11	Status	REF
Acute adrenal insufficiency	N.A.	Approved	[6]
Acute asthma	CA23	Approved	[6]
Addison disease	5A74.0	Approved	[6]
Allergic rhinitis	CA08.0	Approved	[6]
Angioedema	4A00.15	Approved	[6]
Aspiration pneumonitis	N.A.	Approved	[6]
Autoimmune haemolytic anaemia	3A20	Approved	[6]
Blepharoconjunctivitis	N.A.	Approved	[6]
Bursitis	N.A.	Approved	[6]
Cerebral edema	8D60.1	Approved	[6]
Chronic graft versus host disease	N.A.	Approved	[6]
Congenital adrenal hyperplasia	5A71.01	Approved	[6]
Corneal abrasion	NA06.4	Approved	[6]
Corneal ulcer	9A76	Approved	[6]
Crohn disease	DD70	Approved	[6]
Dacryocystitis	N.A.	Approved	[6]
Demodex blepharitis	1G07	Approved	[6]
Dermatitis herpetiformis	EB44	Approved	[6]
Diamond-Blackfan anemia	N.A.	Approved	[6]
Disorder of orbital region	N.A.	Approved	[6]
Epicondylitis	N.A.	Approved	[6]
Erythema multiforme	N.A.	Approved	[6]
Exanthem	N.A.	Approved	[6]
Fever	MG26	Approved	[6]
Granuloma annulare	N.A.	Approved	[6]
Hypersensitivity pneumonitis	N.A.	Approved	[6]
Inflammatory bowel disease	DD72	Approved	[6]
Ischemia-reperfusion injury	DB98.B	Approved	[6]
Keratitis	N.A.	Approved	[6]
Leukemia	N.A.	Approved	[6]
Lupus nephritis	4A40.0Y	Approved	[6]
Microscopic polyangiitis	N.A.	Approved	[6]
Miliary tuberculosis	N.A.	Approved	[6]
Mycosis fungoides	2B01	Approved	[6]
Myeloproliferative neoplasm	2A20	Approved	[6]
Pneumocystis pneumonia	CA40.20	Approved	[6]
Polymyalgia rheumatica	N.A.	Approved	[6]
Primary cutaneous T-cell lymphoma	N.A.	Approved	[6]
Psoriasis	EA90	Approved	[6]
Psoriatic arthritis	FA21	Approved	[6]
Rheumatic heart disease	N.A.	Approved	[6]
Rosacea	ED90.0	Approved	[6]
Sarcoidosis	4B20.5	Approved	[6]
Serum sickness	N.A.	Approved	[6]
Severe asthma	CA23	Approved	[6]
Skin disease	EA00-EM0Z	Approved	[6]
Solid tumour/cancer	2A00-2F9Z	Approved	[7]
Sympathetic ophthalmia	N.A.	Approved	[6]
Systemic lupus erythematosus	4A40.0	Approved	[6]
Ulcerative colitis	DD71	Approved	[6]
Multiple sclerosis	8A40	Phase 3	[8]
Acquired thrombocytopenia	N.A.	Investigative	[6]
Asthma	CA23	Investigative	[6]
Beta-thalassemia major	N.A.	Investigative	[6]
Classic Hodgkin lymphoma	N.A.	Investigative	[6]
Follicular lymphoma	2A80	Investigative	[6]
Iridocyclitis	N.A.	Investigative	[6]
Sjogren syndrome	4A43.20	Investigative	[6]
Synovitis	N.A.	Investigative	[6]
Uveitis	9A96.Z	Investigative	[6]

Prednisolone Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Glucocorticoid receptor (NR3C1)	TTYRL6O	GCR_HUMAN	Modulator	[63]

Prednisolone Interacts with 1 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[64]

Prednisolone Interacts with 2 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[65]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Metabolism	[66]

Prednisolone Interacts with 121 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Increases Expression	[67]
CCN family member 1 (CCN1)	OTKJBEMD	CCN1_HUMAN	Increases Expression	[61]
Phospholipid phosphatase 3 (PLPP3)	OTSSF7BK	PLPP3_HUMAN	Decreases Expression	[61]
Interferon-induced protein with tetratricopeptide repeats 3 (IFIT3)	OTPGHZB9	IFIT3_HUMAN	Decreases Expression	[61]
Calmegin (CLGN)	OTEWVFQV	CLGN_HUMAN	Decreases Expression	[61]
D-3-phosphoglycerate dehydrogenase (PHGDH)	OT1LMRTG	SERA_HUMAN	Decreases Expression	[61]
Receptor-interacting serine/threonine-protein kinase 2 (RIPK2)	OT0KMIYQ	RIPK2_HUMAN	Decreases Expression	[61]
Gasdermin-E (GSDME)	OT1ZWY32	GSDME_HUMAN	Decreases Expression	[61]
Toll-like receptor 2 (TLR2)	OTGO5P4R	TLR2_HUMAN	Decreases Expression	[61]
CCN family member 5 (CCN5)	OTADU8JJ	CCN5_HUMAN	Increases Expression	[61]
Antiviral innate immune response receptor RIG-I (RIGI)	OTFIIC43	RIGI_HUMAN	Decreases Expression	[61]
2'-5'-oligoadenylate synthase 1 (OAS1)	OT8ZLOCY	OAS1_HUMAN	Decreases Expression	[61]
Collagen alpha-1(I) chain (COL1A1)	OTI31178	CO1A1_HUMAN	Increases Expression	[61]
Superoxide dismutase , mitochondrial (SOD2)	OTIWXGZ9	SODM_HUMAN	Decreases Expression	[61]
Ubiquitin-like protein ISG15 (ISG15)	OT53QQ7N	ISG15_HUMAN	Decreases Expression	[61]
Interleukin-6 (IL6)	OTUOSCCU	IL6_HUMAN	Decreases Expression	[61]
Thrombospondin-1 (THBS1)	OT0ECWK3	TSP1_HUMAN	Increases Expression	[61]
Asparagine synthetase (ASNS)	OT8R922G	ASNS_HUMAN	Decreases Expression	[61]
Hepatocyte growth factor receptor (MET)	OT7K55MU	MET_HUMAN	Decreases Expression	[61]
Steryl-sulfatase (STS)	OTXTJQPC	STS_HUMAN	Increases Expression	[61]
Neuromedin-B (NMB)	OT4NLN6H	NMB_HUMAN	Decreases Expression	[61]
Stromelysin-2 (MMP10)	OTJDWW8Q	MMP10_HUMAN	Decreases Expression	[61]
Growth-regulated alpha protein (CXCL1)	OT3WCTZV	GROA_HUMAN	Decreases Expression	[61]
Interferon alpha-inducible protein 6 (IFI6)	OTWOOAM4	IFI6_HUMAN	Decreases Expression	[61]
Interferon-induced protein with tetratricopeptide repeats 1 (IFIT1)	OTXOQDSG	IFIT1_HUMAN	Decreases Expression	[61]
Interleukin-1 receptor antagonist protein (IL1RN)	OT308CBE	IL1RA_HUMAN	Decreases Expression	[61]
C-X-C motif chemokine 2 (CXCL2)	OTEJCYMY	CXCL2_HUMAN	Decreases Expression	[61]
C-X-C motif chemokine 3 (CXCL3)	OTSL94KH	CXCL3_HUMAN	Decreases Expression	[61]
Interferon-induced GTP-binding protein Mx1 (MX1)	OT6X8G5T	MX1_HUMAN	Decreases Expression	[61]
Fibulin-1 (FBLN1)	OT5MHHOP	FBLN1_HUMAN	Increases Expression	[61]
Atypical chemokine receptor 3 (ACKR3)	OTA6GA4F	ACKR3_HUMAN	Decreases Expression	[61]
11-beta-hydroxysteroid dehydrogenase 1 (HSD11B1)	OTO7FJA9	DHI1_HUMAN	Decreases Expression	[61]
Adenosine receptor A2a (ADORA2A)	OTVRBZ0I	AA2AR_HUMAN	Decreases Expression	[61]
CCN family member 2 (CCN2)	OTC39NSU	CCN2_HUMAN	Increases Expression	[61]
Myristoylated alanine-rich C-kinase substrate (MARCKS)	OT7N056G	MARCS_HUMAN	Decreases Expression	[61]
Guanylate-binding protein 1 (GBP1)	OTUM7RPJ	GBP1_HUMAN	Decreases Expression	[61]
Prostaglandin G/H synthase 2 (PTGS2)	OT75U9M4	PGH2_HUMAN	Decreases Expression	[61]
Macrophage metalloelastase (MMP12)	OT9Z7LHM	MMP12_HUMAN	Decreases Expression	[61]
Interferon alpha-inducible protein 27, mitochondrial (IFI27)	OTI2XGIT	IFI27_HUMAN	Decreases Expression	[61]
Regulator of G-protein signaling 4 (RGS4)	OTG94HHL	RGS4_HUMAN	Decreases Expression	[61]
Prolargin (PRELP)	OT9EEBUJ	PRELP_HUMAN	Increases Expression	[61]
Spermine synthase (SMS)	OT8JYKNH	SPSY_HUMAN	Decreases Expression	[61]
C-X-C chemokine receptor type 4 (CXCR4)	OTUFSBX2	CXCR4_HUMAN	Decreases Expression	[61]
C-C motif chemokine 20 (CCL20)	OTUCJY4N	CCL20_HUMAN	Decreases Expression	[61]
DNA-binding protein inhibitor ID-3 (ID3)	OTUULW5Z	ID3_HUMAN	Increases Expression	[61]
Tumor necrosis factor alpha-induced protein 2 (TNFAIP2)	OTRZH80H	TNAP2_HUMAN	Decreases Expression	[61]
Aldehyde oxidase (AOX1)	OT2FZP6H	AOXA_HUMAN	Increases Expression	[61]
Bone marrow stromal antigen 2 (BST2)	OTU4LCJV	BST2_HUMAN	Decreases Expression	[61]
EGF-containing fibulin-like extracellular matrix protein 1 (EFEMP1)	OTZVUOOB	FBLN3_HUMAN	Increases Expression	[61]
Neuronal membrane glycoprotein M6-b (GPM6B)	OT8Q1582	GPM6B_HUMAN	Increases Expression	[61]
Laminin subunit beta-3 (LAMB3)	OTFPU6W8	LAMB3_HUMAN	Decreases Expression	[61]
Nidogen-2 (NID2)	OTHC33FF	NID2_HUMAN	Increases Expression	[61]
Signal transducer and activator of transcription 4 (STAT4)	OTAK3VFR	STAT4_HUMAN	Decreases Expression	[61]
2'-5'-oligoadenylate synthase-like protein (OASL)	OTZ05YRP	OASL_HUMAN	Decreases Expression	[61]
Bcl-2-related protein A1 (BCL2A1)	OTWRYSNA	B2LA1_HUMAN	Decreases Expression	[61]
Lymphocyte antigen 6E (LY6E)	OTMG16BZ	LY6E_HUMAN	Decreases Expression	[61]
Interferon-induced protein 44-like (IFI44L)	OTXKORJP	IF44L_HUMAN	Decreases Expression	[61]
Olfactomedin-like protein 2B (OLFML2B)	OTDNJFR4	OLM2B_HUMAN	Increases Expression	[61]
E3 ubiquitin-protein ligase RNF19B (RNF19B)	OTYCWKBP	RN19B_HUMAN	Decreases Expression	[61]
Amphoterin-induced protein 2 (AMIGO2)	OTPAIT1O	AMGO2_HUMAN	Decreases Expression	[61]
Probable E3 ubiquitin-protein ligase HERC6 (HERC6)	OT7G9PQE	HERC6_HUMAN	Decreases Expression	[61]
Equilibrative nucleobase transporter 1 (SLC43A3)	OTR60ZLA	S43A3_HUMAN	Decreases Expression	[61]
Interferon-induced protein 44 (IFI44)	OTOKSZVA	IFI44_HUMAN	Decreases Expression	[61]
S-adenosylmethionine-dependent nucleotide dehydratase RSAD2 (RSAD2)	OTCA9WCM	RSAD2_HUMAN	Decreases Expression	[61]
Nuclear receptor subfamily 4 group A member 3 (NR4A3)	OTPBE9R1	NR4A3_HUMAN	Decreases Expression	[61]
Type II iodothyronine deiodinase (DIO2)	OTGPNSLH	IOD2_HUMAN	Increases Expression	[61]
Interferon regulatory factor 7 (IRF7)	OTC1A2PQ	IRF7_HUMAN	Decreases Expression	[61]
Interferon-stimulated gene 20 kDa protein (ISG20)	OTCWRJJW	ISG20_HUMAN	Decreases Expression	[61]
Interferon-induced helicase C domain-containing protein 1 (IFIH1)	OTZA2AHA	IFIH1_HUMAN	Decreases Expression	[61]
Anthrax toxin receptor 1 (ANTXR1)	OT5W1GPC	ANTR1_HUMAN	Increases Expression	[61]
Interleukin-23 subunit alpha (IL23A)	OTYO99HC	IL23A_HUMAN	Decreases Expression	[61]
NADH dehydrogenase 1 alpha subcomplex subunit 4-like 2 (NDUFA4L2)	OTK0PG7R	NUA4L_HUMAN	Decreases Expression	[61]
Large neutral amino acids transporter small subunit 2 (SLC7A8)	OT8XXVO8	LAT2_HUMAN	Increases Expression	[61]
E3 ISG15--protein ligase HERC5 (HERC5)	OTZ5PR39	HERC5_HUMAN	Decreases Expression	[61]
Paired immunoglobulin-like type 2 receptor alpha (PILRA)	OTBE0PLF	PILRA_HUMAN	Decreases Expression	[61]
Cystine/glutamate transporter (SLC7A11)	OTKJ6PXW	XCT_HUMAN	Decreases Expression	[61]
Cytochrome P450 2S1 (CYP2S1)	OTKHX4RF	CP2S1_HUMAN	Decreases Expression	[27]
Hydroxymethylglutaryl-CoA synthase, cytoplasmic (HMGCS1)	OTCO26FV	HMCS1_HUMAN	Increases Expression	[62]
Inactive phospholipase C-like protein 1 (PLCL1)	OTJL2C79	PLCL1_HUMAN	Increases Expression	[62]
Cyclin-G2 (CCNG2)	OTII38K2	CCNG2_HUMAN	Increases Expression	[62]
Programmed cell death protein 4 (PDCD4)	OTZ6NXUX	PDCD4_HUMAN	Increases Expression	[62]
Kelch-like protein 24 (KLHL24)	OTWZSX5C	KLH24_HUMAN	Increases Expression	[62]
Protein FAM200C (FAM200C)	OTZOXUEK	F200C_HUMAN	Increases Expression	[62]
Arrestin domain-containing protein 3 (ARRDC3)	OTAKW7R9	ARRD3_HUMAN	Increases Expression	[62]
Sulfiredoxin-1 (SRXN1)	OTYDBO4L	SRXN1_HUMAN	Increases Expression	[62]
Cysteine-rich motor neuron 1 protein (CRIM1)	OTTZNV6Y	CRIM1_HUMAN	Increases Expression	[62]
SLAM family member 5 (CD84)	OTAY5B0F	SLAF5_HUMAN	Increases Expression	[62]
PDZ and LIM domain protein 1 (PDLIM1)	OT4EGCPG	PDLI1_HUMAN	Increases Expression	[68]
Basic helix-loop-helix ARNT-like protein 1 (BMAL1)	OTMI12L2	BMAL1_HUMAN	Increases Expression	[69]
Period circadian protein homolog 2 (PER2)	OTU2B1DJ	PER2_HUMAN	Decreases Expression	[69]
Period circadian protein homolog 1 (PER1)	OTVQF3WX	PER1_HUMAN	Increases Expression	[69]
Transforming growth factor beta-1 proprotein (TGFB1)	OTV5XHVH	TGFB1_HUMAN	Decreases Expression	[70]
Tumor necrosis factor (TNF)	OT4IE164	TNFA_HUMAN	Increases Expression	[71]
Interleukin-1 beta (IL1B)	OT0DWXXB	IL1B_HUMAN	Decreases Expression	[68]
Albumin (ALB)	OTVMM513	ALBU_HUMAN	Increases Expression	[72]
Serotransferrin (TF)	OT41PEMS	TRFE_HUMAN	Increases Expression	[72]
Glucocorticoid receptor (NR3C1)	OTCI2YDI	GCR_HUMAN	Increases Activity	[45]
Insulin-like growth factor I (IGF1)	OTIIZR61	IGF1_HUMAN	Decreases Response To Substance	[73]
Interleukin-4 (IL4)	OTOXBWAU	IL4_HUMAN	Decreases Expression	[74]
Interleukin-5 (IL5)	OTAFPSCO	IL5_HUMAN	Decreases Expression	[74]
Mineralocorticoid receptor (NR3C2)	OT0F2V2Z	MCR_HUMAN	Increases Activity	[45]
Interleukin-8 (CXCL8)	OTS7T5VH	IL8_HUMAN	Decreases Expression	[68]
C-C motif chemokine 3 (CCL3)	OTW2H3ND	CCL3_HUMAN	Increases Expression	[46]
C-C motif chemokine 4 (CCL4)	OT6B8P25	CCL4_HUMAN	Increases Expression	[46]
C-C motif chemokine 2 (CCL2)	OTAD2HEL	CCL2_HUMAN	Decreases Expression	[46]
Ganglioside GM2 activator (GM2A)	OTIRWZC0	SAP3_HUMAN	Increases Expression	[68]
Nuclear receptor subfamily 1 group D member 1 (NR1D1)	OTJ38PTB	NR1D1_HUMAN	Decreases Expression	[69]
C-X-C chemokine receptor type 2 (CXCR2)	OTISGW7L	CXCR2_HUMAN	Decreases Expression	[75]
Long-chain-fatty-acid--CoA ligase 1 (ACSL1)	OTB06ESI	ACSL1_HUMAN	Increases Expression	[68]
Growth/differentiation factor 5 (GDF5)	OTOV8S81	GDF5_HUMAN	Decreases Expression	[76]
Tissue factor pathway inhibitor 2 (TFPI2)	OTZCRWOR	TFPI2_HUMAN	Decreases Expression	[68]
Transcription factor SOX-9 (SOX9)	OTVDJFGN	SOX9_HUMAN	Decreases Expression	[68]
D site-binding protein (DBP)	OTE0W7LN	DBP_HUMAN	Decreases Expression	[69]
Cryptochrome-1 (CRY1)	OTTGAJT0	CRY1_HUMAN	Decreases Expression	[69]
Mucin-16 (MUC16)	OTHPPE67	MUC16_HUMAN	Decreases Expression	[77]
Lymphocyte antigen 96 (LY96)	OTN4HXA2	LY96_HUMAN	Decreases Expression	[68]
DNA topoisomerase 1 (TOP1)	OT51O0CF	TOP1_HUMAN	Increases ADR	[78]
Histone-lysine N-methyltransferase 2A (KMT2A)	OT9GLJI6	KMT2A_HUMAN	Decreases Response To Substance	[79]
11-beta-hydroxysteroid dehydrogenase type 2 (HSD11B2)	OTHF4H9U	DHI2_HUMAN	Increases Metabolism	[80]
Mothers against decapentaplegic homolog 1 (SMAD1)	OTQSHR25	SMAD1_HUMAN	Increases ADR	[78]
Catenin beta-1 (CTNNB1)	OTZ932A3	CTNB1_HUMAN	Increases ADR	[78]

References

• [1] ClinicalTrials.gov (NCT03936517) Safety and Efficacy of Prednisolone in Adrenal Insufficiency Disease (PRED-AID Study)
• [2] Hydrocortisone FDA Label
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2868).
• [4] Hydrocortisone for COVID-19 and Severe Hypoxia (COVID STEROID)
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Prednisolone FDA Label
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [8] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2866).
• [9] Hydrocortisone enhances the barrier properties of HBMEC/ci, a brain microvascular endothelial cell line, through mesenchymal-to-endothelial transition-like effects. Fluids Barriers CNS. 2015 Mar 5;12:7. doi: 10.1186/s12987-015-0003-0. eCollection 2015.
• [10] Effect of cortisol on cell proliferation and the expression of lipoprotein lipase and vascular endothelial growth factor in a human osteosarcoma cell line. Cancer Chemother Pharmacol. 2008 Mar;61(3):471-9. doi: 10.1007/s00280-007-0492-x. Epub 2007 Jun 5.
• [11] Peripheral CLOCK regulates target-tissue glucocorticoid receptor transcriptional activity in a circadian fashion in man. PLoS One. 2011;6(9):e25612. doi: 10.1371/journal.pone.0025612. Epub 2011 Sep 28.
• [12] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [13] Oral and inhaled corticosteroids: differences in P-glycoprotein (ABCB1) mediated efflux. Toxicol Appl Pharmacol. 2012 May 1;260(3):294-302.
• [14] Regulation of the CYP3A4 gene by hydrocortisone and xenobiotics: role of the glucocorticoid and pregnane X receptors. Drug Metab Dispos. 2000 May;28(5):493-6.
• [15] CYP3A5 genotype is associated with elevated blood pressure. Pharmacogenet Genomics. 2005 Oct;15(10):737-41.
• [16] Steroid hydroxylation by human fetal CYP3A7 and human NADPH-cytochrome P450 reductase coexpressed in insect cells using baculovirus. Res Commun Mol Pathol Pharmacol. 1998 Apr;100(1):15-28.
• [17] Studies on the origin of circulating 18-hydroxycortisol and 18-oxocortisol in normal human subjects. J Clin Endocrinol Metab. 2004 Sep;89(9):4628-33.
• [18] Steroid signalling in the ovarian surface epithelium. Trends Endocrinol Metab. 2005 Sep;16(7):327-33.
• [19] Receptor-dependent regulation of the CYP3A4 gene. Toxicology. 2002 Dec 27;181-182:199-202.
• [20] Induction of hepatic CYP3A enzymes by pregnancy-related hormones: studies in human hepatocytes and hepatic cell lines. Drug Metab Dispos. 2013 Feb;41(2):281-90.
• [21] Oral and inhaled corticosteroids: differences in P-glycoprotein (ABCB1) mediated efflux. Toxicol Appl Pharmacol. 2012 May 1;260(3):294-302. doi: 10.1016/j.taap.2012.03.008. Epub 2012 Mar 23.
• [22] Monomeric and oligomeric flavanols maintain the endogenous glucocorticoid response in human macrophages in pro-oxidant conditions in vitro. Chem Biol Interact. 2018 Aug 1;291:237-244.
• [23] Overexpression of glutathione-S-transferase A1 in benign adrenocortical adenomas from patients with Cushing's syndrome. J Clin Endocrinol Metab. 2001 Apr;86(4):1653-9.
• [24] Keratinocyte differentiation marker suppression by arsenic: mediation by AP1 response elements and antagonism by tetradecanoylphorbol acetate. Toxicol Appl Pharmacol. 2001 Aug 1;174(3):302-11.
• [25] Testosterone stimulates adipose tissue 11beta-hydroxysteroid dehydrogenase type 1 expression in a depot-specific manner in children. J Clin Endocrinol Metab. 2010 Jul;95(7):3300-8.
• [26] Ultradian cortisol pulsatility encodes a distinct, biologically important signal. PLoS One. 2011 Jan 18;6(1):e15766.
• [27] CYP2S1 is negatively regulated by corticosteroids in human cell lines. Toxicol Lett. 2012 Feb 25;209(1):30-4.
• [28] Towards a systematic analysis of human short-chain dehydrogenases/reductases (SDR): Ligand identification and structure-activity relationships. Chem Biol Interact. 2015 Jun 5;234:114-25.
• [29] Glucocorticoid-activation system mediated glucocorticoid-insulin-like growth factor 1 (GC-IGF1) axis programming alteration of adrenal dysfunction induced by prenatal caffeine exposure. Toxicol Lett. 2019 Mar 1;302:7-17.
• [30] Glucocorticoid programming mechanism for hypercholesterolemia in prenatal ethanol-exposed adult offspring rats. Toxicol Appl Pharmacol. 2019 Jul 15;375:46-56.
• [31] Differential regulation of Toll-like receptor and CD14 pathways by retinoids and corticosteroids in human sebocytes. Dermatology. 2006;213(3):266. doi: 10.1159/000095056.
• [32] Differential regulation of the human MRP2 and MRP3 gene expression by glucocorticoids. J Steroid Biochem Mol Biol. 2005 Aug;96(3-4):229-34. doi: 10.1016/j.jsbmb.2005.03.004.
• [33] Effect of hydrocortisone on the maturation of human foetal kidney explants in serum-free organ culture. Biochem Cell Biol. 1989 Feb-Mar;67(2-3):121-7. doi: 10.1139/o89-019.
• [34] Acute effects of hydrocortisone on plasma nitrate/nitrite activity and forearm vasodilator responsiveness in normal human subjects. Clin Exp Pharmacol Physiol. 2005 Mar;32(3):162-6. doi: 10.1111/j.1440-1681.2005.04173.x.
• [35] Stress doses of hydrocortisone reduce severe systemic inflammatory response syndrome and improve early outcome in a risk group of patients after cardiac surgery. Crit Care Med. 2003 Apr;31(4):1068-74. doi: 10.1097/01.CCM.0000059646.89546.98.
• [36] Experimental studies on cortisol-induced hypertension in humans. J Hum Hypertens. 1995 Jun;9(6):395-9.
• [37] Effects of cortisol and cocaine on plasma prolactin and growth hormone levels in cocaine-dependent volunteers. Addict Behav. 2005 May;30(4):859-64. doi: 10.1016/j.addbeh.2004.08.019.
• [38] Neuropeptide Y in cortisol-induced hypertension in male volunteers. Clin Exp Pharmacol Physiol. 1994 May;21(5):435-8. doi: 10.1111/j.1440-1681.1994.tb02538.x.
• [39] Profiling the immunotoxicity of chemicals based on in vitro evaluation by a combination of the Multi-ImmunoTox assay and the IL-8 Luc assay. Arch Toxicol. 2018 Jun;92(6):2043-2054. doi: 10.1007/s00204-018-2199-7. Epub 2018 Mar 29.
• [40] Role of erythropoietin in cortisol-induced hypertension. J Hum Hypertens. 2000 Mar;14(3):195-8. doi: 10.1038/sj.jhh.1000959.
• [41] Intergenerational genetic programming mechanism and sex differences of the adrenal corticosterone synthesis dysfunction in offspring induced by prenatal ethanol exposure. Toxicol Lett. 2021 Oct 15;351:78-88. doi: 10.1016/j.toxlet.2021.08.007. Epub 2021 Aug 25.
• [42] A glucocorticoid-responsive mutant androgen receptor exhibits unique ligand specificity: therapeutic implications for androgen-independent prostate cancer. Endocrinology. 2002 May;143(5):1889-900. doi: 10.1210/endo.143.5.8778.
• [43] Deducing signaling pathways from parallel actions of arsenite and antimonite in human epidermal keratinocytes. Sci Rep. 2020 Feb 19;10(1):2890. doi: 10.1038/s41598-020-59577-0.
• [44] Regulation of messenger RNAs for the hydrophobic surfactant proteins in human lung. J Clin Invest. 1989 Apr;83(4):1191-7. doi: 10.1172/JCI114000.
• [45] Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties. Eur J Endocrinol. 2004 Sep;151(3):397-406. doi: 10.1530/eje.0.1510397.
• [46] Cell-based and cytokine-directed chemical screen to identify potential anti-multiple myeloma agents. Leuk Res. 2010 Jul;34(7):917-24. doi: 10.1016/j.leukres.2009.12.002. Epub 2010 Feb 8.
• [47] Screening of some anti-androgenic endocrine disruptors using a recombinant cell-based in vitro bioassay. J Steroid Biochem Mol Biol. 2004 Feb;88(2):157-66. doi: 10.1016/j.jsbmb.2003.11.005.
• [48] Negative regulation of hepatocyte growth factor gene expression in human lung fibroblasts and leukemic cells by transforming growth factor-beta 1 and glucocorticoids. J Biol Chem. 1992 Dec 15;267(35):24917-20.
• [49] Tacrolimus ointment causes inflammatory dendritic epidermal cell depletion but no Langerhans cell apoptosis in patients with atopic dermatitis. J Allergy Clin Immunol. 2004 Jul;114(1):137-43. doi: 10.1016/j.jaci.2004.03.021.
• [50] Prenatal caffeine exposure increases the susceptibility to non-alcoholic fatty liver disease in female offspring rats via activation of GR-C/EBP-SIRT1 pathway. Toxicology. 2019 Apr 1;417:23-34. doi: 10.1016/j.tox.2019.02.008. Epub 2019 Feb 15.
• [51] P2Y receptor regulation of sodium transport in human mammary epithelial cells. Am J Physiol Cell Physiol. 2007 Nov;293(5):C1472-80. doi: 10.1152/ajpcell.00068.2007. Epub 2007 Aug 22.
• [52] Influence of cocaine dependence and early life stress on pituitary-adrenal axis responses to CRH and the Trier social stressor. Psychoneuroendocrinology. 2010 Nov;35(10):1492-500. doi: 10.1016/j.psyneuen.2010.05.001. Epub 2010 May 31.
• [53] Relation of oxytocin to psychological stress responses and hypothalamic-pituitary-adrenocortical axis activity in older women. Psychosom Med. 2006 Mar-Apr;68(2):238-45. doi: 10.1097/01.psy.0000203242.95990.74.
• [54] Human and murine steroid 5-reductases (AKR1D1 and AKR1D4): insights into the role of the catalytic glutamic acid. Chem Biol Interact. 2019 May 25;305:163-170. doi: 10.1016/j.cbi.2019.03.025. Epub 2019 Mar 28.
• [55] Steroid profiling in H295R cells to identify chemicals potentially disrupting the production of adrenal steroids. Toxicology. 2017 Apr 15;381:51-63.
• [56] Interferon- is a potent inhibitor of cell growth and cortisol production in vitro and sensitizes human adrenocortical carcinoma cells to mitotane. Endocr Relat Cancer. 2013 May 30;20(3):443-54. doi: 10.1530/ERC-12-0217. Print 2013 Jun.
• [57] Overexpression of RbAp46 facilitates stress-induced apoptosis and suppresses tumorigenicity of neoplastigenic breast epithelial cells. Int J Cancer. 2003 Jul 20;105(6):762-8. doi: 10.1002/ijc.11148.
• [58] Stimulation of progesterone, estradiol and cortisol in trophoblast tumor bewo cells by glycodelin A N-glycans. Anticancer Res. 2007 Jul-Aug;27(4A):2101-8.
• [59] Melatonin exerts direct inhibitory actions on ACTH responses in the human adrenal gland. Horm Metab Res. 2011 May;43(5):337-42. doi: 10.1055/s-0031-1271693. Epub 2011 Feb 17.
• [60] Low estriol levels in the maternal triple-marker screen as a predictor of isolated adrenocorticotropic hormone deficiency caused by a new mutation in the TPIT gene. Pediatrics. 2006 Feb;117(2):e322-7. doi: 10.1542/peds.2005-1973. Epub 2006 Jan 3.
• [61] Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
• [62] Transcriptome-based functional classifiers for direct immunotoxicity. Arch Toxicol. 2014 Mar;88(3):673-89.
• [63] Aldosterone (mineralocorticoid) equivalent to prednisolone (glucocorticoid) in reversing hearing loss in MRL/MpJ-Fas1pr autoimmune mice. Laryngoscope. 2000 Nov;110(11):1902-6.
• [64] The role of the efflux transporter P-glycoprotein in brain penetration of prednisolone. J Endocrinol. 2002 Oct;175(1):251-60.
• [65] Inter-individual difference determinant of prednisolone pharmacokinetics for Japanese renal transplant recipients in the maintenance stage. Xenobiotica. 2009 Dec;39(12):939-45.
• [66] Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in adrenalectomized rats. J Pharmacokinet Biopharm. 1999 Feb;27(1):1-21.
• [67] Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor. Biol Pharm Bull. 2003 Apr;26(4):510-7.
• [68] Gene expression profiling of rheumatoid arthritis synovial cells treated with antirheumatic drugs. J Biomol Screen. 2007 Apr;12(3):328-40. doi: 10.1177/1087057107299261. Epub 2007 Mar 22.
• [69] Chronic treatment with prednisolone represses the circadian oscillation of clock gene expression in mouse peripheral tissues. Mol Endocrinol. 2006 Mar;20(3):573-83. doi: 10.1210/me.2005-0165. Epub 2005 Nov 3.
• [70] Steroid therapy and urinary transforming growth factor-beta1 in IgA nephropathy. Am J Kidney Dis. 2001 Dec;38(6):1191-8. doi: 10.1053/ajkd.2001.29209.
• [71] Contrasting effects of steroids and angiotensin-converting-enzyme inhibitors in a mouse model of dystrophin-deficient cardiomyopathy. Eur J Heart Fail. 2009 May;11(5):463-71. doi: 10.1093/eurjhf/hfp028. Epub 2009 Feb 20.
• [72] Prednisolone can increase glomerular permeability to proteins in nephrotic syndrome. Kidney Int. 1988 Jun;33(6):1169-74. doi: 10.1038/ki.1988.126.
• [73] Anti-TNF antibody treatment improves glucocorticoid induced insulin-like growth factor 1 (IGF1) resistance without influencing myoglobin and IGF1 binding proteins 1 and 3. Ann Rheum Dis. 2006 Mar;65(3):301-5. doi: 10.1136/ard.2005.040816. Epub 2005 Aug 3.
• [74] JTP-27536 [(+)-1,3-dihydroxy-2-hydroxymethylpropyl-2-ammonium 2-[(R)-3-cyclo-hexyl-1-phenylpropyl]-1,3-dioxo-2,3-dihydro-1H-isoindole-5-carboxylate monohydrate], a novel inhibitor of immunoglobulins and interleukin-5 with anti-inflammatory properties in mouse allergic dermatitis model. J Pharmacol Exp Ther. 2005 Jul;314(1):293-301. doi: 10.1124/jpet.104.080846. Epub 2005 Apr 8.
• [75] CXCR2 Expression on neutrophils is upregulated during the relapsing phase of ocular Behcet disease. Curr Eye Res. 2005 Mar;30(3):195-203. doi: 10.1080/02713680490904331.
• [76] Modulatory effects of inflammation and therapy on GDF-5 expression in rheumatoid arthritis synovium. Scand J Rheumatol. 2008 Nov-Dec;37(6):401-9. doi: 10.1080/03009740802120010.
• [77] Dermatomyositis associated with membranous nephropathy in a 43-year-old female. Am J Nephrol. 2002 Jul-Aug;22(4):385-8. doi: 10.1159/000065233.
• [78] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [79] In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype. Leukemia. 2004 Mar;18(3):521-9. doi: 10.1038/sj.leu.2403253.
• [80] Metabolism of synthetic steroids by the human placenta. Placenta. 2007 Jan;28(1):39-46.